# Biomea Fusion (BMEA) — News

BMEA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/bmea/news

## Recent headlines

- [Banca Mediolanum: BofA global research raises price objective to EUR 25.5 from EUR 24.5](https://www.ainvest.com/news/banca-mediolanum-bofa-global-research-raises-price-objective-eur-25-5-eur-24-5-2610) — AInvest Wire, Oct 15, 2026
  Bank of America’s global research team has raised its price objective for Banca Mediolanum (BMEDM) to EUR 25.5 from EUR 24.5, reflecting improved expectations for the Italian financial services group. The adjustment follows strong performance in 2025, during which Banca Mediolanum reported a record…
- [Biomea Fusion: Confinement appears to have affected eating behavior for cohort 5 participants, believe its results should be interpreted separately](https://www.ainvest.com/news/biomea-fusion-confinement-appears-affected-eating-behavior-cohort-5-participants-results-interpreted-separately-2610) — AInvest Wire, Oct 13, 2026
  Biomea Fusion (Nasdaq: BMEA) has indicated that confinement conditions may have influenced eating behaviors among participants in cohort 5 of one of its clinical studies, suggesting that the results from this group should be analyzed independently from other cohorts. This observation highlights the…
- [Biomea Fusion to SEK BMF-650 late-stage development partner](https://www.ainvest.com/news/biomea-fusion-sek-bmf-650-late-stage-development-partner-2610) — AInvest Wire, Oct 13, 2026
- [Biomea fusion - Cohort 5 shows 6.1% mean weight reduction at day 29, 1.55 kg per week](https://www.ainvest.com/news/biomea-fusion-cohort-5-shows-6-1-weight-reduction-day-29-1-55-kg-week-2610) — AInvest Wire, Oct 13, 2026
  Biomea Fusion Inc. has released preliminary data from Cohort 5 of its ongoing clinical trials, indicating a mean weight reduction of 6.1% at day 29, equivalent to an average of 1.55 kg per week. The results are part of the company’s broader research into its fusion-based therapeutic approach for…
- [Biomea fusion - All adverse events in five mad cohorts were mild or moderate](https://www.ainvest.com/news/biomea-fusion-adverse-events-mad-cohorts-mild-moderate-2610) — AInvest Wire, Oct 13, 2026
  Biomea Fusion, Inc. (Nasdaq: BMEA) reported that all adverse events observed across five cohorts in its clinical trials involving the investigational drug icovamenib were classified as mild or moderate . These findings were part of the 52-week results from the Phase 2 COVALENT-112 trial, which…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).